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Abstract  
 
Wiskott-Aldrich syndrome is a severe X-linked recessive immune deficiency 
disorder. A scoring system of Wiskott-Aldrich syndrome severity (0.5-5) 
distinguishes 2 phenotypes: X-linked thrombocytopenia and classic Wiskott-
Aldrich syndrome. Hematopoietic cell transplantation is curative for Wiskott-
Aldrich syndrome, however the use of unrelated umbilical cord blood 
transplantation has seldom been described. We analyzed umbilical cord blood 
transplantation outcomes for 90 patients. Median age at umbilical cord blood 
transplantation was 1.5 years.  Patients were classified according to clinical 
scores (2 (23%), 3 (30%), 4 (23%) and 5 (19%)). Most patients received HLA 
mismatched umbilical cord blood transplantation and myeloablative conditioning 
with anti-thymocyte globulin. Cumulative incidence of neutrophil recovery at 
day-60 was 89% and day-100 acute graft-versus-host disease grade II-IV was 
38%; use of methotrexate for graft-versus- host disease prophylaxis delayed 
engraftment (p=0.02), but decreased acute graft-versus-host disease (p=0.03). At 
5-year, overall survival and event-free survival were 75% and 70%, respectively. 
Estimated 5 year- event-free survival was 83%, 73% and 55% for patients with 
clinical score 2, 4-5 and 3, respectively. In multivariate analysis, age<2years at 
umbilical cord blood transplantation and clinical phenotype X-linked 
thrombocytopenia were associated with improved event-free survival. Overall 
survival tended to be improved after 2007 (p=0.09). In conclusion, umbilical cord 
blood transplantation is a good alternative option for young children with 
Wiskott-Aldrich syndrome lacking an HLA identical stem cell donor. 
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Introduction 
 
Wiskott-Aldrich syndrome (WAS) is a severe X-linked recessive immune deficiency 
disorder caused by mutations in the gene encoding for Wiskott-Aldrich syndrome 
protein (WASP), a key regulator of actin polymerization signaling and cytoskeletal 
reorganization in hematopoietic cells
1-3
. A mutation in WASP results in a wide spectrum 
of clinical manifestations ranging from the relatively mild X-linked thrombocytopenia 
(XLT) to the classic WAS phenotype characterized by microthrombocytopenia, 
immunodeficiency, eczema, and high susceptibility to lymphoproliferative tumors and 
autoimmune diseases. 
2,4,5
 A simple scoring system on a scale of 0.5 to 5 was introduced 
to differentiate XLT from classic WAS patients based on the severity of the clinical 
phenotype (supplemental table 1). 
6
 
XLT patients (score <3) have excellent overall survival (OS), but have, also, a high 
probability of severe disease-related complications
7
. In contrast, the classic WAS (score 
≥3) usually leads to death in early childhood or adolescence, despite advances in clinical 
care, with median life expectancy of only 15 years. 
6,8,9
  
Currently, the only proven curative therapy for patients with WAS is hematopoietic stem 
cell transplantation (HSCT).
6,10
 Various series of HSCT from HLA-matched related 
donors (MRDs) have consistently resulted in survival rates above 80% for patients with 
WAS 
11-15
. In the absence of a MRD, the OS reported after matched unrelated HSCT has 
been around 70%
11
. In the last 20 years, unrelated donor umbilical cord blood 
transplantation (UCBT) has become an option for patients lacking a HLA matched 
donor
16
. To date, there are only few reports on outcomes after UCBT for patients with 
primary immune deficiencies, 
17-19
 but they include only a few patients with WAS, 
18,20-22
 
and none of the studies have analyzed factors associated with outcomes after UCBT. 
Therefore, we conducted a collaborative multi-center retrospective risk factor analysis 
of patients with WAS reported to Eurocord. A total of 90 UCBT recipients met the 
criteria and were included in the study.  
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Methods 
 
Data collection 
 
This retrospective analysis is based on data reported to EBMT and/or Eurocord from 
European and non-European transplant centers through a standardized questionnaire 
that included information on patients, donors, diseases, and transplant outcomes. 
Missing information was requested in the form of a Microsoft Excel file listing 
transplantations performed by each centre along with key data extracted from the 
Eurocord-EBMT databases. In addition, data from Duke University Medical Center 
(USA), Federal University of Parana (Brazil) and Pontifical Catholic University of Chile 
were obtained from the respective center. Recipient’s parents or legal guardians gave 
informed consent for HSCT according to the Declaration of Helsinki. Eurocord and the 
Working Party of Inborn Errors of EBMT approved this study. 
Inclusion criteria 
 
The inclusion criteria for the study were: (1) Patients transplanted for WAS before 
December 31, 2013, and reported to Eurocord; (2) First allogeneic unrelated HSCT.  
Patients were excluded from the study if diagnosis of immune deficiency was not 
specified or if transplants were performed with a cord blood unit that was expanded, 
combined with other HSC source, or injected intra-bone. 
Endpoints and definitions  
 
The primary endpoint was: event-free survival (EFS), defined as survival from 
transplantation to last contact without any of the following events: autologous 
reconstitution (defined by documentation of <5% donor derived engraftment), graft 
failure (defined as a lack of neutrophil recovery or transient engraftment of donor cells 
after transplantation, and/or a requirement for a second transplant) and death. All 
surviving patients were censored at the date of last contact.  
Other endpoints reported included: (1) overall survival (OS), defined as time from 
transplantation to death of any cause; (2) Cumulative incidence of neutrophil 
engraftment, defined as the first day of achieving a neutrophil count of ≥0.5x10
9
/L for 3 
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consecutive days with evidence of donor hematopoiesis; (3) Cumulative incidence of 
platelet engraftment defined as the first of 3 consecutive days post-HSCT with a platelet 
count ≥20x10
9
/L without platelet transfusions for at least seven days; (4) Graft failure: 
primary failure defined as neutrophil never reaching 0.5x10⁹/L or evidence of 
autologous reconstitution; secondary graft failure defined as reaching a neutrophil count 
of 0.5x10⁹/L after transplant, but experiencing a subsequent, non-transitory, decrease, 
or loss of donor chimerism; and (5) Incidence of acute- and chronic graft versus host 
disease (GvHD; acute-GvHD grade II-IV was diagnosed and graded according to 
published criteria.
23
 Chronic-GvHD was graded according to standard criteria
24
 and 
evaluated in patients who survived at least 100 days with sustained engraftment. 
Myeloablative conditioning regimen was defined as conditioning including an 
intravenous busulfan (IV Bu) total dose of more than 6.4 mg/kg or an oral dose greater 
than 8 mg/kg/day, or treosulfan (Treo) >36 mg/m
2 
for infants (less than 12 months old) 
and >42 mg/m
2
 for
 
others.
 
Other regimens were considered reduced intensity 
conditioning (RIC).  
Donor-recipient HLA matching was defined considering low resolution typing for HLA 
Class I (A and B) and high resolution typing for HLA Class II (DRB1). Donor-recipient 
chimerism was reported on the basis of available data during the first 100 ±30 days, 1-
year ±30 days after UCBT and at the last chimerism evaluation. Full-donor chimerism 
was defined as the presence of ≥95% donor-derived hematopoietic cells, mixed-
chimerism as 5% to 94% of these cells and autologous recovery if <5%.  
Immune phenotyping results (CD3
+
CD4
+
 and CD3
+
CD8
+
 T-lymphocytes; CD19
+
 B 
lymphocytes) were measured at 100 ±30 days, 1-year ±30 days and at the last 
assessment reported after UCBT.  As normal values in childhood vary considerably with 
age, absolute numbers of CD4+, CD8+ and CD19 were related to age-specific normal 
values.
25,26
 Immune recovery was defined as being alive with neutrophil engraftment 
and achieving absolute number of CD4+, CD8+ and CD19+ within the age-related normal 
values as shown in a supplemental table 2.  
Statistical analysis 
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To analyze risk factors for outcomes, we considered factors related to patient (median 
age at diagnosis, median age at transplant, median weight at time of transplantation, 
gender, pre-transplant CMV serology status, Lansky score), disease (pre-transplant 
information on: infections, severe thrombocytopenia (platelets<20x10
9
/L), number of 
platelets transfusion, platelet abnormalities, history of severe bleeding, splenectomy, 
presence of eczema, autoimmunity, malignancy, congenital neutropenia, clinical 
phenotype, median interval from date of birth to diagnosis, median interval time from 
diagnosis to transplant)], cord blood unit (HLA matching, median collected and infused 
total nucleated cell and CD34+cell doses), and factors related to transplantation (year of 
transplant, use of RIC or MAC, type of GvHD prophylaxis).   
Cumulative incidence curves were calculated for neutrophil, platelet engraftment, acute 
and chronic GvHD in a competing risk setting, with death as a competing event 
27
.  Gray 
test was used for univariate comparisons. Probabilities of EFS and OS were calculated 
using the Kaplan-Meier estimate; the two-sided log-rank test was used for univariate 
comparisons.  Multivariate analysis were performed using Cox proportional hazard 
regression model 
28
 for EFS and OS, and proportional sub distribution hazard regression 
model of Fine and Gray for acute and chronic GvHD, neutrophil and platelets 
engraftment. Variables, which reached a p-value 0.10 in the univariate analysis, and 
other relevant factors such as HLA matching and cell dose, were included in the initial 
models and variables were eliminated one by one at a time in a stepwise fashion in 
order to only keep variables that reached a p-value of 0.05 in the final model. P-values 
were two-sided. Statistical analyses were performed using SPSS (Inc., Chicago) and S-
Plus (MathSoft, Inc., Seattle) software packages.  
Results 
Patient, donor, and transplant characteristics 
 
Ninety patients with a clinical diagnosis of WAS who received UCBT between 1996 and 
2013 in 33 centers from 20 countries met the eligibility criteria for the study. The 
baseline patient, donor, and transplantation characteristics are shown in table 1. Disease 
severity before transplantation was expressed as a WAS score of 2 to 5. Eighteen 
patients (23%) had a WAS clinical score of less than 3 at the time of UCBT, indicating 
that they had not experienced any of the following: severe infections, difficult-to-treat 
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eczema, autoimmunity, or malignancy. The majority of patients (n= 61, 77%) had severe 
clinical features of the disease at the time of transplantation, including 52 patients with a 
history of recurrent and/or severe infections. Seven patients had a history of 
autoimmune disorders and two of EBV associated lymphoproliferative disease.  
Four patients were splenectomized before UCBT, of whom two had a platelet count 
<20x10⁹cells/L at the time of transplantation. All of the splenectomized patients had the 
classic WAS clinical phenotype and three experienced severe infection before UCBT. 
Data on WAS gene mutations were available for 39 patients (43%). Almost an equal 
proportion of patients carried nonsense, missense and deletion mutations.  
The median age at transplant was 1.48 years (range 4.8 months – 14.25 years).  Only 9 
patients were more than 5 years old at the time of UCBT. Most patients (76%) had a 
good performance status at the time of UCBT (Lansky score >80%). 
The vast majority of children were conditioned with a busulfan containing 
myeloablative regimen (97%), mainly busulfan/cyclophosphamide (76%). Three 
patients received reduced-intensity conditioning, two of them due to severe infection at 
time of UCBT. Most patients received anti-thymocyte globulin (ATG) (n=79). All patients 
who received GvHD prophylaxis received a calcineurin inhibitor containing regimen, 
consisting of either CsA (in most of cases) or Tacrolimus. The median number of total 
nucleated cell and CD34+ cell doses infused were 6.8 x 10
7
 cells/kg and 3.04 x 10
5
/kg 
(pre-cryopreservation counts), respectively. 
 
Neutrophil and platelets recovery 
 
Eighty patients (89%) achieved neutrophil engraftment, with a median time to 
engraftment of 21 days (range, 9-54). The cumulative incidence (CI) of neutrophil 
engraftment was 70%, and 89% at day 30 and 60, respectively. Ten (11%) patients did 
not achieve neutrophil engraftment. Of the patients who failed to engraft, 4 received a 
second transplantation and were alive at last follow-up, and the 6 who did not receive a 
second HSCT, died. 
Multivariate analysis showed that use of methotrexate (MTX) in GvHD prophylaxis (HR 
0.55, 95% CI 0.32-0.93, p=0.02) was associated with lower CI of neutrophil engraftment.  
At day 180, CI of platelet engraftment was 75%, with a median time to engraftment of 45 
days (range, 11-224). Platelet engraftment in the 4 splenectomized patients seemed 
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faster with median time of 35 days. Due to small number of splenectomized patients, it 
was not possible to confirm if there was a real impact of this procedure in the 
engraftment rate. In univariate analysis, the only risk factor associated with lower CI of 
platelet engraftment was age more than 2 years (67% vs. 79% for younger patients, p= 
0.03). Multivariate analysis confirmed that age was independently associated with 
platelets engraftment (HR 0.34, 95% CI 0.16-0.73, p=0.005).  
Chimerism and immune recovery 
 
Chimerism data was available for 66 (86%) out of 77 evaluable patients at 100 (±30) 
days post-UCBT, 50 (80%) out of 63 patients at 1-year (±30 days) post-UCBT, and 51 
(82%) out of 62 patients at last assessment. At day 100, 68% of patients were full donor 
and 32% mixed chimerism; at 1 year, 76% and 24%, respectively and at last assessment, 
80% and 20%, respectively. In 12 cases, mixed chimera became full donor in a further 
assessment, and 2 patients who were, initially, full donor became stable mixed chimera 
at last assessment.  
Information on the absolute number of CD3/4
+
, CD3/8
+
 and CD19
+
 lymphocytes at 
100±30 days, 1 year±30 days after UCBT and at the latest assessment was available in 
29, 25 and 25 of the patients who were alive with neutrophil engraftment at specific 
time-points, respectively.  In this subset analysis, 31 (67%) out of 46 patients achieved 
IR. Median time between UCBT and the first reported immune recovery testing was 12 
months; eleven patients achieved IR before the first 12 months after transplantation, the 
earliest confirmed IR was reported 4 months after UCBT. Fifteen patients did not 
achieve IR. Of these, 13 patients were being treated with immunosuppressive agents due 
to acute GvHD, remaining two patients, who had no history of GvHD, had mixed 
chimerism results.  
Acute and chronic GvHD 
 
Acute GvHD grade II-IV was observed in 35 patients (22 - experienced grade II (24%), 8 
- grade III (8%), and 5 - grade IV (6%)). The CI of acute GvHD II-IV at day 100 was 38%. 
In univariate analysis, none of the factors analyzed were significantly associated with an 
increased risk of grade II-IV GvHD.  However, in multivariate analysis, the use of MTX for 
GvHD prophylaxis was associated with decreased incidence of grade II-IV GvHD (22% 
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vs. 42%) (HR 0.34, CI 95% 0.12-0.91, p=0.03). CI of chronic GvHD at 5 years was 17% 
(n=15; 6 extensive and 9 limited cases). In univariate analysis, cumulative incidence of 
chronic GvHD decreased after 2007 (25% vs. 3%, p<0.01). Chronic GvHD also decreased 
for patients receiving a TNC cell dose lower than 6.8 x10
7
/kg, (23% vs. 7%, p=0.03). In 
multivariate analysis, none of the risk factors studied were significantly associated with 
an increased risk of chronic GvHD. 
Overall survival, event-free survival and causes of death  
 
The probability of 5-year overall survival (OS) and event-free survival (EFS) were 
75±5% and 70±5%, respectively. Table 2 shows the univariate analysis of risk factors 
for OS and EFS. The risk factors associated with worst OS in multivariate analysis (table 
3) were: age >2 years at UCBT [HR: 2.61, 95%CI: 1.1-6.16; p=0.02] and clinical score > 2 
(XLT) [HR: 4.49; 95%CI: 1.02-19.78; p=0.04] (Figure 1-2). There was a trend of 
improved OS in patients transplanted after 2007 [HR 2.27, 0.86-5.98, p=0.09] (Figure 3).  
In multivariate analysis for EFS, older children (more than 2 year) at UCBT also had 
significantly worse prognosis [HR: 2.47, 95%CI: 1.1-5.52; p=0.02]. Sixty-seven patients 
were alive at last assessment, with a median follow-up of 5 years (range, 0.25-17). 
Twenty-three (25%) patients died. Table 4 shows causes of death before and after 100 
days post UCBT, according to WAS score.  Infection related deaths were commonly 
observed among all disease scores, and it was the main cause of death, especially before 
day 100. 
 
Discussion  
 
This multicenter, retrospective study on UCBT recipients with WAS confirms that for 
most patients, HSCT using HLA matched or mismatched CB cells can cure and prevent 
the long-term, life-threatening complications associated with WAS.  Outcomes of 
patients with WAS who do not undergo HSCT remain poor, with the mean age of death 
of 20 years in previous reports
9
 and with increasing risk of malignancies with age. 
Several groups
11
,
16
, 
15
 reported successful HSCT results  with an OS of up to 88% when 
using a “gold standard donor” 
14
. In the absence of a matched related donor (MRD), other 
groups have reported the successful use of matched unrelated donors with 71% OS 
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11,29,30
, but with higher risk of acute and chronic GvHD. Unfortunately, many patients do 
not have an available matched unrelated donor. Therefore, other donor sources for 
transplantation have been investigated, such as the use of T-cell depleted haploidentical 
HSCT and umbilical cord blood HSCT. Nowadays, the results after haploidentical HSCT 
with TcRαβ/CD19-depletion for patients with PID seem promising
31
. On the other hand, 
UCB is still attractive due to the naivety of the stem cells, the lower HLA matching 
requirements, and easy availability (compared to MRD and MUD) and decreased GvHD 
(compared to haploidentical HSCT)
32
.  
We have conducted a risk factor analysis for this rare disease using retrospective-
registry based data. The limitations of our study, is mainly due to some missing data 
related to the disease and the long inclusion period with changes in cord blood unit 
selection and better supportive care in most recent years. Despite these limitations, the 
study remains noteworthy, as it is the largest series of children with WAS treated with 
UCBT.  
We were able to identify mainly 2 main factors associated with EFS and OS after 
UCBT: age at UCBT and clinical disease score (Figure 1-2).  EFS and OS were significantly 
improved when transplantation was performed before 2 years of age with almost 80% 
of these young patients cured. This finding supports the need for early referral for 
transplantation in infants diagnosed with WAS. We could speculate that older children 
could have more previous complications before UCBT, which, in turn, could affect 
outcomes.  However, in patients with available data, we determined that OS and EFS 
were not associated with number of previous infections, Lansky score, severity of 
eczema, thrombocytopenia, and number of previous platelets transfusions, 
autoimmunity and congenital neutropenia.  
Clinical score was also a prognostic factor. As expected, patients with XLT (score 
<3) had improved OS and EFS when compared with other clinical phenotypes. XLT 
patients have, historically, excellent OS without transplantation in contrast to patients 
with classic WAS. However, EFS in XLT patients seem to worsen over time
33,34
. Data 
from the XLT registry showed EFS of 74% at 15 years, decreasing to 56% by 30 years, 
without subsequent transplantation. Currently, there is no consensus on indication of 
HSCT in XLT and decision on HSCT for such patients has to be made on individual basis
7
.  
In our cohort, 23% of the patients were classified as having score 2, and there were no 
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patient with score 0.5 or 1 (table 1), showing that some degree of severity was present 
to justify the transplantation. We found that patients with a clinical score of 3 seemed to 
have worse probabilities of OS and EFS, however due to small number of patients in the 
groups, we were not able to draw any definitive conclusions. 
The most frequent cause of death after UCBT was infection. The majority of 
patients in our series received ATG as part of the conditioning regimen, which may 
explain the high number of infection related deaths observed. 
35
 Infections are 
commonly seen after UCBT due to delayed engraftment and impaired immune recovery 
mainly when ATG is used before UCBT
36
.  
We were able to analyze immune recovery in a subset of patients. We found that 
67% of the 46 patients with available information achieved immune recovery. Median 
time between UCBT and first test reporting IR was 12 months, and eleven patients 
achieved IR before first 12 months after transplantation. These results seem comparable 
to the IR usually observed after UCBT. 
26
 However, due to the retrospective nature of our 
analysis, we were unable to collect data on IVIG use details and vaccine-specific antibody 
response; therefore the IR results reported here should be taken with caution. Most 
patients who did not achieve IR were treated with immune suppressive agents due to 
acute GvHD, which may explain our findings.  
Mixed chimerism post-transplant is an undesirable outcome following HSCT for 
WAS since it may be associated with lymphopenia, autoimmunity and 
thrombocytopenia. 
16
 In our series, chimerism data was available for 86% of the patients 
during 3 months, 12 months and last assessment. Full donor chimerism was observed in 
68%, 76% and 80% of the patients, respectively. In a recent study of chimerism in 194 
HSCT recipients with WAS, 72.1% of patients achieved full and stable donor 
chimerism.
16
 In this study was also shown that mixed chimerism impacts the myeloid 
compartment (16.5% of cases), followed by B cell compartment (7.4% of cases) and 
uncommonly the T-cell compartment (3.2% of cases). Unfortunately, in our series, we 
did not have data on lineage specific chimerism, however our results are comparable 
with the 72% full donor chimera seen with other HSC sources. 
We were unable to identify cord blood donor related factors associated with 
outcomes. Previously, the Eurocord group has reported that for UCBT recipients with 
non-malignant disorders, a cell dose higher than 5x10
7
/kg and a 6/6 or 5/6 HLA grafts 
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are associated with decreased mortality
35
. In our study, patients were transplanted with 
a median cell dose of 7.5 x10
7
/kg and 70% received a 6/6 or 5/6 CB graft, which is in 
agreement with the recommendations for cord blood selection for patients with non-
malignant disorders.  
In conclusion, early referral for UCBT in patients with WAS is associated with 
better outcomes. New treatment strategies such as autologous gene-modified HSCT may 
overcome the disadvantages of graft rejection and GvHD after allogeneic HSCT. 
However, until these strategies become clinically available, UCBT remains a good 
alternative for patients lacking an HLA matched donor.  
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Tables  
Table1. Baseline patient, disease, donor and transplantation characteristics. 
 
 N =90 (%*) Median (range) 
Patient characteristics 
  
Gender (Male/Female) 88/2  
Weight, kg  10.25 (5-51.7) 
Age at diagnosis, years  0.32 (0-8.3) 
Time interval diagnosis- UCBT, years  1.05 (0.06-13.05) 
Age at transplantation, years  1.48 (0.40-14.25) 
≤5  81  
> 5  9  
CMV before UCBT   
Seropositive 47(70)  
Seronegative  20 (30)  
Disease characteristics 
  
WAS clinical phenotype at UCBT   
Severe infections 52 (68)  
Eczema   
Mild 19 (28)  
Moderate 35 (51)  
Severe 14 (21)  
Severe thrombocytopenia (<20x10⁹cells/L) 43 (70)  
Microthrombocytopenia 22 (51)  
Life-threatening bleeding 41 (59)  
Malignancies 2 (4)  
Autoimmunity 7 (13)  
Congenital neutropenia 9 (19)  
WAS score   
2 18 (23)  
3 24 (30)  
4 18 (23)  
5 19 (24)  
Splenectomy before UCBT 4 (5)  
Donor characteristics 
  
HLA-matching   
6/6  11 (12)  
5/6  52 (58)  
4/6  25 (28)  
3/6  1  
Cell dose   
Collected NC (x10
7
/kg) 
 7.5 (0.2-3) 
Collected CD34+ (x10
5
/kg)  
 3.03 (0.03-35) 
Transplant characteristics   
Year of transplantation  2007 (1996-2013) 
Conditioning regimen   
MAC 87 (97)  
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Cy/Bu 67  
Cy/Bu+others 8  
Bu/Fluda 6  
Fluda/Treo42 5  
Cy/Hydroxyurea 1  
RIC 3  
Cy/Bu 1  
Fluda/Melph ± Treo36 1/1  
GvHD prophylaxis   
CNI/Pred 49 (54)  
CNI/MTX 17 (20)  
CNI/MMF 11 (12)  
CNI 9 (10)  
CNI/others 3 (3)  
Non given 1 (1)  
Serotherapy   
Anti-T serotherapy (before day 0) 
79 (89)  
Monoclonal Antibody 
2 (2)  
Not given 8 (9)  
* Percentage of evaluable cases 
UCBT indicates umbilical cord blood transplantation; CMV, cytomegalovirus; WAS, Wiskott-
Aldrich syndrome; NC, nucleated cells; MAC, myeloablative conditioning regiment; Cy, 
cyclophosphamide; Bu, busulphan; Fluda, fludarabine; Treo, treosulphan; GvHD, “graft-versus-
host” disease; CNI, calcineurin inhibitor; Pred, prednisolone. 
 
Table 2. Probability of 5-year overall and event-free survival   after UCBT for WAS  
    
5y OS  % 
(95%CI) 
  
5y EFS  % 
(95%CI) 
  
Variable N   P   P 
Patients characteristics 
Age at UCBT, years 
 ≤ 2 years 60 83 (71-91) 
.027 
78 (67-86) 
.05 
> 2 years 30 58 (41-74) 55 (38-71) 
CMV status 
negative 19 77 (54-91) 
.9 
73 (51-88) 
.9 
positive 47 80 (66-89) 74 (59-85) 
Weight at UCBT, kg 
<10 45 89 (76-96) 
 .002 
82 (68-91) 
.02 
≥ 10 
45 60 (44-74) 58 (42-72) 
Splenectomy 
Yes 4 50 (15-85) 
0.2 
50 (15-85) 
.33 
No 75 76 (42-93) 72 (61-81) 
Lansky score, % 
<90 19 67 (44-84) 
.63 
57 (34-77) 
.2 
≥ 90 59 76 (63-86) 74 (61-84) 
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Disease characteristics 
Clinical score 
2 18 89 (69-97) 
.03 
83 (61-94) 
.18 
3 24 61 (41-77) 55 (35-75) 
4 18 78 (55-91) 72 (50-88) 
5 19 79 (57-91) 74 (52-88) 
UCBT characteristics 
HLA-match 
6/6 11 71 (41-90) 
.9 
61 (33-83) 
.75 5/6 53 76 (63-86) 72 (59-82) 
4/6 or 3/6 26 72 (52-86) 69 (50-83) 
ABO-compatibility 
no incompatibility 36 70 (47-86) 
.8 
72 (55-850 
.9 minor  incompatibility 17 76 (58-88) 70 (47-86) 
major  incompatibility 29 70 (49-85) 70 (51-84) 
Year of UCBT 
Before 2007 51 69 (54-81) 
.13 
65 (51-77) 
.2 
After 2007 39 83 (66-93) 78 (62-51) 
Time from diagnosis to UCBT 
< 7 months  23 91 (73-97) 
.14 
86 (68-95) 
.18 
7-13 months 22 80 (56-93) 76 (53-90) 
>13-19 months 22 72 (50-87) 68 (47-83) 
> 19 months 22 58 (37-77) 54 (34-73) 
Conditioning regimen 
Cy/Bu/ATG 25 83 (64-93) 
.2 
83 (60-91) 
.3 
others 65 72 (60-81) 67 (55-77) 
GvHD prophylaxis 
MTX 18 74 (63-83) 
.7 
70 (57-80) 
.7 
others 72 78 (54-91) 72 (48-88) 
Cell doses 
TNC collected, x10
7
/kg 
< 7  43 72 (57-83) 
.43 
67 (52-79) 
.4 
≥ 7 42 77 (61-88) 73 (58-84) 
TNC infused,  x10
6
/kg 
<  6 43 77 (61-88) 
.8 
74 (59-85) 
.5 
≥ 6 42 72 (57-83) 65 (49-79) 
CD34+collected, x10
6
/kg 
< 3 34 68 (51-81) 
.2 
62 (46-76) 
.12 
≥  3 33 78 (59-90) 75 (57-87) 
CD34+ infused, x10
5
/kg 
Less than 3 34 66 (52-78) 
.11 
74 (59-85) 
.14 
At least 3 33 86 (64-95) 75 (57-87) 
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UCBT indicates umbilical cord blood transplantation; WAS, Wiskott-Aldrich syndrome; OS, 
overall survival; EFS, event-free survival; CI, confidence interval; CMV, cytomegalovirus; 
Cy, cyclophosphamide; Bu, busulphan; ATG, anti-thymocyte globulin; GvHD, graft-versus-
host disease; TNC, total nucleated cells. 
 
Table 3. Multivariate analysis for OS and EFS 
  HR 95% CI P 
OS Older than 2 years 4.49 1.02-19.78 .04 
WAS score more than 2 2.61 1.1-6.16 .02 
UCBT after 2007  2.27 0.86-5.98 .09 
EFS Older than 2 years 2.47 1.1-5.52 .02 
WAS score more than 2 3.13 0.9-10.87 .07 
UCBT after 2007  1.68 0.7-4.04 .24 
OS indicates overall survival; EFS, event-free survival; HR, Hazard ratio; CI, confidence 
interval; WAS, Wiskott-Aldrich syndrome; UCBT, umbilical cord blood transplantation.  
 
Table 4. Primary causes of death before and after 100 days after UCBT for WAS 
Primary causes of death WAS clinical score Total number 
 2 3 4 5 Unknown  
N deaths/N total 2/18 11/24 4/18 4/19 2/11  
Before 100 d 1 5  1  7 
Viral infection  3    3 
Fungal infection 1   1  2 
Bacterial infection  1    1 
Unknown infection  1    1 
After 100 d 1 6 4 3 2 16 
Infection  5  1 1 7 
GvHD 1   2  3 
Multiorgan failure   2   2 
Unknown   1  1 2 
Interstitial pneumonitis   1   1 
Hemorrhage  1    1 
UCBT indicates umbilical cord blood transplantation; WAS, Wiskott-Aldrich syndrome; GvHD, 
“graft-versus-host” disease. 
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Figures legends 
 
Figure 1. Probability of overall survival after umbilical cord blood transplantation for 
Wiskott-Aldrich syndrome according to age.  
Figure 2. Probability of event-free survival after umbilical cord blood transplantation for 
Wiskott-Aldrich syndrome according to clinical score.   
Figure 3. Probability of overall survival after umbilical cord blood transplantation for 
Wiskott-Aldrich syndrome according to year. 
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Supplemental	  table	  	  
Table	  1.	  WAS	  scoring	  system	  to	  define	  clinical	  phenotypes	  
	  
XLT	   WAS	  Score	   0.5	   1	   2	   3	   4	   5	  Thrombocytopenia	   -­‐/+	   +	   +	   +	   +	   +	  Small	  platelets	   -­‐	   +	   +	   +	   +	   +	  Eczema	   -­‐	   -­‐	   (+)	   +	   ++	   (+)/+/++	  Immunodeficiency	   -­‐	   -­‐/(+)	   (+)	   +	   +	   (+)/+	  Infections	   -­‐	   -­‐	   (+)	   +	   +/++	   (+)/+/++	  Autoimmunity	  and/or	  malignancy	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   +	  WAS	  indicates	  Wiskott-­‐Aldrich	  syndrome;	  XLT,	  X-­‐linked	  thrombocytopenia.	  Scoring	   system:	   -­‐/(+),	   absent	   or	  mild;	   -­‐/+,	   intermittent	   thrombocytopenia;	   (+),	  mild	   transient	  eczema	  or	  mild	  infrequent	  infections	  not	  resulting	  in	  sequelae;	  +,	  thrombocytopenia,	  persistent	  but	   therapy-­‐responsive	   eczema,	   and	   recurrent	   infections	   requiring	   antibiotics	   and	   often	   IVIG	  prophylaxis;	   ++,	   eczema	   that	   is	   difficult	   to	   control	   and	   severe,	   life-­‐threatening	   infections.	  Because	  patients	  with	  XLT	  may	  develop	  autoimmune	  disorders	  or	  lymphoma	  (albeit	  at	  a	  lower	  rate	  than	  those	  with	  classic	  WAS),	  a	  progression	  from	  a	  score	  of	  1	  or	  full	  donor	  to	  a	  score	  of	  5	  is	  possible	  for	  XLT.	  	  
Table	  2.	  Median	  and	  range	  of	  absolute	  number	  (x10⁹/L)	  of	  CD4+,	  CD8+	  and	  CD19+	  at	  first	  
reported	  test	  confirmed	  IR,	  compared	  to	  median	  and	  percentiles	  (5th	  to	  95th	  percentiles)	  
of	   absolute	   numbers	   (x10⁹/L)	   of	   normal	   values	   of	   CD4+,	   CD8+	   and	   CD19+;	   number	   of	  
patients	  survived,	  achieved	  engraftment	  and	  IR	  by	  age	  groups1.	  	  
	   5-­‐9	  mo.	   9-­‐15	  mo.	   15-­‐24	  mo.	   2-­‐5	  yr.	   5-­‐10	  yr.	   10-­‐18	  yr.	  
	   Absolute	  number	  (x10⁹/L)	   Healthy	  children	   Median	  (range)	   Healthy	  children	   Median	  (range)	   Healthy	  children	   Median	  (range)	   Healthy	  children	   Median	  (range)	   Healthy	  children	   Median	  (range)	   Healthy	  children	  CD4+	   4.3	  	   2.8	  (1.4-­‐5.1)	   2.02	  (1.9-­‐2.1)	   2.3	   (1.4-­‐4.6)	   1.35	  (0.7-­‐2.6)	   2.2	  (0.9-­‐5.5)	   1.33	  (0.09-­‐3.9)	   1.3	  (0.5-­‐2.4)	   0.6	  (0.28-­‐2.7)	   1.0	  (0.3-­‐2.0)	   0.8	  (0.3-­‐1.2)	   0.8	  (0.4-­‐2.1)	  CD8+	   1.75	   1.1	  (0.6-­‐2.2)	   0.8	  (0.6-­‐5.2)	   1.1	   (0.4-­‐2.1)	   0.4	  (0.17-­‐1.4)	   1.2	  (0.4-­‐2.3)	   0.6	  (0.04-­‐6.2)	   0.8	  (0.3-­‐1.6)	   1.05	  (0.1-­‐1.2)	   0.8	  (0.3-­‐1.8)	   0.36	  (0.02-­‐1.5)	   0.4	  (0.2-­‐12)	  CD19+	   1.49	   1.3	  (0.7-­‐2.5)	   1.41	  (0.3-­‐1.4)	   1.4	  (0.6-­‐2.7)	   1.4	  (0.89-­‐2.7)	   1.3	  (0.6-­‐3.1)	   1.09	  (0.001-­‐2.2)	   0.8	  (0.2-­‐2.1)	   0.95	  (0.5-­‐2.1)	   0.5	  (0.2-­‐1.6)	   0.79	  (0.03-­‐1.7)	   0.3	  (0.2-­‐0.6)	  	  References	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